CARMAT Launches a Capital Increase for an Amount of c. 30 Million Euros That Has Received Subscription Commitments Totaling 22 Million Euros

Regulatory News:

NOT FOR RELEASE, EITHER DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

CARMAT (FR0010907956, ALCAR) (Paris:ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative to people suffering from end-stage biventricular heart failure (the “Company”), today announces the launch of a c. 30 million euros capital increase via the issuance of new shares at a fixed price of 10.0 euros per share aimed at specialized and strategic investors, as defined below, and at individuals (via the PrimaryBid platform) (the “Global Offering”).

The Company is planning to use the funds raised through this Global Offering to ensure the continuity of its activities, and notably to support the restart of the production of its Aeson artificial heart and ensure the resumption – scheduled for October 2022 – of its implants, both from a commercial standpoint and within the framework of its clinical trials.

Stéphane Piat, Chief Executive Officer of CARMAT, commented: “The funds raised via the operation we are launching today will strengthen our financial structure and allow us to calmly ensure the resumption of implants of our Aeson artificial heart from October 2022. Indeed, the constructive dialogue we are having with the competent authorities and the notified body DEKRA, as well as the recent restarting of our production, following the incorporation of changes enabling us to strengthen the sturdiness of the various components, give us confidence in our ability to resume our clinical trials and sales as expected and thus address the strong expectations of physicians and patients. The support of our longstanding shareholders is particularly important during this crucial period for the Company, and I would particularly like to emphasize their substantial commitment. I am also pleased that we are able to offer other investors, as well as individuals - via the PrimaryBid system - the possibility of contributing to the development of our Company and its unique technology that we more than ever feel has the potential to radically and lastingly change the care and treatment provided to patients with end-stage biventricular heart failure”.